Article
Cyclin-dependent kinase (CDK) 4/6 inhibition in non-small cell lung cancer with epidermal growth factor receptor (EGFR) mutations.
Investigational new drugs - 1 Apr 2023
Osoegawa Atsushi, Takumi Yohei, Hashimoto Takafumi, Nakatsuji Shotaro, Hori Mayu, Sakai Mayu, Karashima Takashi, Abe Miyuki, Miyawaki Michiyo, Sugio Kenji
Abstract excerpt
BACKGROUND: Lung cancer is the leading cause of cancer death worldwide, and EGFR mutation is the most common genetic alteration among Asian patients with lung adenocarcinoma. While osimertinib has been shown to be effective in lung cancer patients with EGFR mutation, the majority of patients eventually develop acquired resistance to treatment. We explored the significance of the cyclin D1 expression in patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.